{
    "name": "casirivimab/imdevimab",
    "comment": "Investigational",
    "other_names": [
        "REGEN-COV"
    ],
    "classes": [
        "COVID-19",
        "Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/regen-cov-casirivimab-imdevimab-4000144",
    "pregnancy": {
        "common": [
            "Insufficient data to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Use during pregnancy only if the potential benefit outweighs the potential risk for the mother and fetus"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are unknown regarding presence in human or animal milk, effects on breastfed infants, or effects on milk production",
            "Maternal IgG is known to be present in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Drug interaction overview"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "Potential for serious hypersensitivity reaction, including anaphylaxis",
                        "If signs and symptoms occur, immediately discontinue IV infusion and initiate appropriate medications and/or supportive care",
                        "Infusion-related reactions reported, including fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness"
                    ]
                },
                {
                    "type": "Severe COVID-19",
                    "description": [
                        "Treatment benefit not observed in patients hospitalized due to COVID-19",
                        "Monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation",
                        "Therefore, casirivimab and imdevimab are not authorized for use in patients",
                        "who are hospitalized due to COVID-19, OR",
                        "who require oxygen therapy due to COVID-19, OR",
                        "who require an increase in baseline oxygen flow rate due to COVID-19 in those on long-term oxygen therapy due to underlying non-COVID-19-related comorbidity"
                    ]
                },
                {
                    "type": "Viral variants",
                    "description": [
                        "Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies ",
                        "Prescribing clinicians should consider prevalence of casirivimab/imdevimab resistant variants in their area ",
                        "Health care providers should review antiviral resistance information provided by state and local health departments ",
                        "Variant proportions circulating in the US can be monitored at the ",
                        "CDC website"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site reactions",
            "percent": "12"
        },
        {
            "name": "Infusion",
            "percent": "1.5"
        },
        {
            "name": "related reactions",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Intestinal obstruction",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Anaphylactic reactions",
            "percent": null
        }
    ]
}